Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable file. CIT can also broadcast NIH-only or HHS-only content.

A Chemist (Re)discovers How The Immune System Kills TB

Loading video...

 
   
Air date: Wednesday, March 4, 2009, 4:15:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 128 * This only includes stats from October 2011 and forward.
Category: Immunology
Runtime: 00:54:29
Description: Dr. Barry received his Ph.D. in organic and bioorganic chemistry in 1989 from Cornell University, studying the biosynthesis of complex natural products. Following postdoctoral research at Johns Hopkins University, Dr. Barry joined NIAID's Rocky Mountain Laboratories. In 1998, he was tenured as chief of the Tuberculosis Research Section (TBRS). He is very involved in international activities to develop new chemotherapies for tuberculosis, serving as an advisor to the World Health Organization and the Global Alliance for TB Drug Development. Dr. Barry is a member of several editorial boards and has authored more than 60 research publications in tuberculosis since entering the field 10 years ago.

The TBRS is an integrated group of chemists, clinicians, and microbiologists dedicated to improving the chemotherapy of tuberculosis. Through a detailed understanding of Mycobacterium tuberculosis (Mtb)-the natural history of the disease, the advantages and shortcomings of current antibiotics, models for the evaluation of new antibiotics, and the underlying reasons for the development of drug resistance-section scientists work to identify new strategies to improve therapy. Translating these strategies into clinically useful drugs engages the chemistry portion of the group in areas such as chemical modification of promising new synthetic antitubercular compounds, identification and optimization of products derived from natural sources with antitubercular activity, and development of novel delivery methods and formulations.

Don't miss this talk!

http://www3.niaid.nih.gov/labs/aboutlabs/lcid/tuberculosisResearchSection/

For more information, visit
The Immunology Interest Group
Debug: Show Debug
NLM Title: A chemist (re)discovers how the immune system kills TB / Barry Clifton ; Immunology Interest Group.
Author: Clifton, Barry.
National Institutes of Health (U.S.). Immunology Interest Group.
Publisher:
Abstract: (CIT): Dr. Barry received his Ph.D. in organic and bioorganic chemistry in 1989 from Cornell University, studying the biosynthesis of complex natural products. Following postdoctoral research at Johns Hopkins University, Dr. Barry joined NIAID's Rocky Mountain Laboratories. In 1998, he was tenured as chief of the Tuberculosis Research Section (TBRS). He is very involved in international activities to develop new chemotherapies for tuberculosis, serving as an advisor to the World Health Organization and the Global Alliance for TB Drug Development. Dr. Barry is a member of several editorial boards and has authored more than 60 research publications in tuberculosis since entering the field 10 years ago. The TBRS is an integrated group of chemists, clinicians, and microbiologists dedicated to improving the chemotherapy of tuberculosis. Through a detailed understanding of Mycobacterium tuberculosis (Mtb)-the natural history of the disease, the advantages and shortcomings of current antibiotics, models for the evaluation of new antibiotics, and the underlying reasons for the development of drug resistance-section scientists work to identify new strategies to improve therapy. Translating these strategies into clinically useful drugs engages the chemistry portion of the group in areas such as chemical modification of promising new synthetic antitubercular compounds, identification and optimization of products derived from natural sources with antitubercular activity, and development of novel delivery methods and formulations.
Subjects: Antitubercular Agents--therapeutic use
Drug Design
Mycobacterium tuberculosis--immunology
Tuberculosis, Pulmonary--drug therapy
Tuberculosis, Pulmonary--immunology
Publication Types: Lecture
Webcasts
Download: To download this event, select one of the available bitrates:
[384k]    How to download a Videocast
NLM Classification: WF 360
NLM ID: 101501574
CIT Live ID: 7450
Permanent link: https://videocast.nih.gov/launch.asp?14937